FDA names Tracy Høeg as interim head of drug evaluation division

December 3 The U.S. Food and Drug Administration announced on Wednesday that Tracy Beth Heg has been named the acting director of the Center for Drug Evaluation and Research. This appointment comes shortly after Richard Pazdur, the agency's longtime oncology leader, announced his retirement just weeks into his tenure.

Pazdur had stepped into the role on November 11, following the resignation of George Tidmarsh, who left amid significant concerns regarding his personal conduct.

Analysis: FDA Appoints Tracy Beth Høeg as Acting Director

The U.S. Food and Drug Administration (FDA) has appointed Tracy Beth Høeg as the acting director of the Center for Drug Evaluation and Research. This announcement came on December 3, following the unexpected retirement of Richard Pazdur, who had only recently taken on the role. His retirement, just weeks into his tenure, follows the resignation of George Tidmarsh, who left amid concerns about his personal conduct. The shift in leadership at such a critical juncture raises questions about stability and direction within the FDA.

Høeg's appointment marks a significant change for the agency, especially given the recent turmoil within the Center. While Pazdur was expected to bring continuity and expertise to the role, his departure leaves a gap in the leadership of one of the FDA's most vital departments. As acting director, Høeg will face immediate challenges, including maintaining the agency’s critical role in drug evaluation and ensuring public trust amidst recent leadership changes.

The timing of these leadership shifts, occurring so close together, highlights potential underlying issues within the agency’s management and may prompt closer scrutiny of its internal dynamics. Stakeholders in both the public and private sectors will be closely monitoring Høeg's tenure to assess whether she can navigate these challenges effectively and stabilize the Center’s operations.

Sources:

• FDA appoints Tracy Høeg as acting director of drug evaluation segment